Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23701602 | 0.87 | RXFP1 (0.53) | RXFP1 | |
| SCHEMBL22556320 | 0.87 | RXFP1 (0.53) | RXFP1 | |
| SCHEMBL22556375 | 0.82 | MEN1 (0.55) | KMT2ARXFP1MAPTJAK2 | |
| SCHEMBL30463745 | 0.82 | MEN1 (0.55) | KMT2ARXFP1MAPTJAK2 | |
| SCHEMBL27157329 | 0.78 | KMT2A (0.48) | KMT2AABL1RIN1MAPTKDM4E | |
| SCHEMBL27157338 | 0.76 | KMT2A (0.50) | KMT2AABL1RIN1MAPTKDM4E | |
| SCHEMBL23411576 | 0.75 | KMT2A (0.68) | KMT2APTPN2PTPN1PTPN6ABL1 | |
| SCHEMBL27157319 | 0.75 | KMT2A (0.47) | KMT2AABL1RIN1MAPTKDM4E | |
| SCHEMBL29716354 | 0.74 | PTPN2 (0.77) | KMT2APTPN2PTPN1PTPN6TGFBR1 | |
| SCHEMBL25362245 | 0.74 | PTPN2 (0.54) | KMT2APTPN2PTPN1PTPN6ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | KMT2A 2329/4885RXFP1 3511/4885PTPN2 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.